Young man looking out of a window

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects millions of children and adults worldwide, impacting their ability to focus, control impulses, and manage daily activities. ADHD is a developmental disorder characterized by an ongoing pattern of one or more of the following types of symptoms: Inattention, such as having difficulty paying attention, keeping on task, or staying organized · Hyperactivity, such as often moving around (including during inappropriate times), feeling restless, or talking excessively · Impulsivity, such as interrupting, intruding on others, or having trouble waiting one's turn.

While ADHD was once viewed primarily as a childhood condition, research now confirms that it often persists into adulthood. It is well established that it can persist into adulthood, with an estimated worldwide prevalence of around 2.5%. Understanding ADHD's complex nature, including its symptoms, causes, and treatment options, is essential for those affected by the condition and their families.

Table of Contents

  • What Is ADHD?
  • Prevalence and Impact
  • Causes and Risk Factors
  • Types of ADHD
  • Symptoms Across the Lifespan
  • Diagnosis and Assessment
  • Treatment Options
  • Living with ADHD
  • Frequently Asked Questions
  • Find a Therapist

What Is ADHD?

ADHD is classified as a neurodevelopmental disorder, meaning it involves differences in brain development and function that affect attention, behavior, and self-control. ADHD is placed within the manual's chapter "Neurodevelopmental Disorders." According to the DSM-5-TR, neurodevelopmental disorders "are characterized by developmental deficits or differences in brain processes that produce impairments of personal, social, a[cademic, or occupational functioning]."

Recent neuroimaging research has provided insights into the brain differences associated with ADHD. Researchers at the National Institutes of Health (NIH) have discovered that symptoms of attention-deficit/hyperactivity disorder (ADHD) are tied to atypical interactions between the brain's frontal cortex and information processing centers deep in the brain. The researchers examined more than 10,000 functional brain images of youth with ADHD and published their results in the American Journal of Psychiatry.

Prevalence and Impact

ADHD affects a significant portion of the population across all age groups:

Children and Adolescents

A random effect meta-analysis of these studies showed that the global prevalence of ADHD in children and adolescents was 8.0% (95% CI 6.0-10%). The prevalence estimate was twice as high in boys (10%) compared to girls (5%). In the United States specifically, estimates of ADHD diagnosis among U.S. children have increased from approximately 6–8% in 2000 to approximately 9–10% in 2018.

Adults

The impact of ADHD extends well beyond childhood. In 2023, an estimated 15.5 million U.S. adults had an ADHD diagnosis, approximately one half of whom received their diagnosis in adulthood. Additionally, up to 70% of individuals with childhood-onset ADHD continue to experience impairing symptoms as adults, even if they no longer meet the criteria for a formal diagnosis.

Gender Differences

ADHD presents differently across genders, with notable disparities in diagnosis patterns. Research identifies several differences between men and women in symptoms and experiences of ADHD. For example, women are more likely to have inattentive symptoms than hyperactive symptoms, which may be less likely to lead to a referral and diagnosis.

Causes and Risk Factors

The exact causes of ADHD remain complex and multifaceted, involving genetic, neurobiological, and environmental factors:

Genetic Factors

The heritability of ADHD is approximately 74%. This high heritability indicates that ADHD runs strongly in families, though having a genetic predisposition doesn't guarantee developing the condition.

Environmental Factors

Several prenatal and early-life exposures have been linked to increased ADHD risk:- Exposure to certain chemicals prenatally and in childhood can impact development and may increase risk for attention-deficit/hyperactivity disorder (ADHD).

  • Specific chemicals of concern include lead, mercury, organophosphates, and polychlorinated biphenyls.- Some risk factors include birth weight < 1500 g, head trauma, iron deficiency, obstructive sleep apnea, and lead exposure, as well as prenatal exposure to alcohol, tobacco, and possibly cocaine.

Neurobiological Differences

Evidence implicates differences in dopaminergic and noradrenergic systems with decreased activity or stimulation in upper brain stem and frontal-midbrain tracts. These neurotransmitter system differences contribute to the attention and impulse control challenges characteristic of ADHD.

Types of ADHD

The DSM-5-TR recognizes three presentations of ADHD:

1. Predominantly Inattentive Presentation

The inattentive type of ADHD (ADHD-I) was found to be the most common type of ADHD. This type is characterized by:

  • Difficulty sustaining attention
  • Problems with organization and time management
  • Forgetfulness in daily activities
  • Tendency to lose things necessary for tasks

2. Predominantly Hyperactive-Impulsive Presentation

This type involves:

  • Excessive physical movement and restlessness
  • Difficulty sitting still
  • Interrupting others frequently
  • Acting without thinking about consequences

3. Combined Presentation

The most comprehensive type, featuring significant symptoms from both inattentive and hyperactive-impulsive categories. Diagnosis of the combined type requires ≥ 6 symptoms and signs each of inattention and hyperactivity/impulsivity.

Symptoms Across the Lifespan

ADHD symptoms evolve throughout life, presenting differently at various developmental stages:

Childhood Symptoms

Children show hyperactivity and impulsivity as the most common symptoms. As academic and social demands increase, symptoms of inattention often become more prominent and begin to interfere with academic performance and peer relationships.

Common childhood symptoms include:

  • Difficulty paying attention in class
  • Frequent careless mistakes in schoolwork
  • Trouble following multi-step instructions
  • Excessive talking and physical movement
  • Difficulty waiting turns during games or activities

Adolescent Symptoms

During the teenage years, hyperactivity often decreases while inattention and executive function challenges become more prominent. Adolescents may struggle with:

  • Time management and meeting deadlines
  • Organizing complex school projects
  • Maintaining focus during lengthy tasks
  • Managing increased academic demands

Adult Symptoms

ADHD symptoms may change as a person gets older. In adults, symptoms often manifest as:

  • Chronic disorganization
  • Poor time management
  • Difficulty prioritizing tasks
  • Problems maintaining employment
  • Relationship difficulties
  • Financial management challenges

Diagnosis and Assessment

Diagnostic Criteria

The DSM-5-TR outlines specific criteria for diagnosing ADHD:

■ Six or more symptoms of inattention and/or hyperactivity-impulsivity for children up to age 16 years, OR · ■ Five or more symptoms of inattention and/or hyperactivity-impulsivity for adolescents ages 17 years and older and adults.

Additional requirements include:- Several inattentive or hyperactive-impulsive symptoms were present before age 12 years.- Several symptoms are present in two or more settings (such as at home, school or work; with friends or relatives; in other activities).- There is clear evidence that the symptoms interfere with, or reduce the quality of, social, school, or work functioning.

Assessment Process

Diagnosing ADHD is a process with several steps. A comprehensive evaluation typically includes:

  • Detailed clinical interviews
  • Review of developmental history
  • Assessment of symptoms across multiple settings
  • Rating scales completed by multiple informants
  • Evaluation for co-occurring conditions
  • Medical examination to rule out other causes

Diagnostic Challenges

DSM-5-TR authors state that "no biological marker is diagnostic for ADHD" and that "meta-analysis of all neuroimaging studies do not show differences between individuals with ADHD and control subjects," thus "no form of neuroimaging can be used for diagnosis of ADHD." This means diagnosis relies primarily on clinical assessment rather than laboratory tests.

Treatment Options

Effective ADHD treatment typically involves a multimodal approach combining medication, behavioral interventions, and lifestyle modifications:

Medication

Stimulant Medications

Stimulants remain the first-line pharmacological treatment for ADHD. They can be highly effective. They work by increasing levels of brain chemicals involved in thinking and attention. However, access can be challenging: Approximately one third of adults with ADHD take stimulant medication; 71.5% had difficulty filling their prescription because the medication was unavailable.

Non-Stimulant Medications

There are now nonstimulant medications that are FDA-approved for treatment of ADHD across the lifespan. These provide alternatives for those who cannot tolerate stimulants or have contraindications.

Psychosocial Interventions

Behavioral Therapy

Behavioral therapy helps a person change their behavior. It might involve practical assistance, such as organizing tasks or completing schoolwork, learning social skills, or monitoring one's behavior.

Cognitive Behavioral Therapy (CBT)

Cognitive behavioral therapy helps a person become aware of attention and concentration challenges and work on skills to improve focus and organization and complete daily tasks (for instance, by breaking large tasks into smaller, more manageable steps).

Research supports the effectiveness of psychosocial approaches: Psychosocial approaches, including individual and group cognitive-behavioral therapy, may also help control symptoms of adult ADHD.

Combined Treatment Approaches

Combination treatment approaches may also be of value in augmenting partial response to a stimulant, or as a replacement strategy. Many individuals benefit most from integrating multiple treatment modalities.

Impact on Quality of Life

Treatment can significantly improve quality of life. In addition to being efficacious in reducing ADHD core symptom severity, both stimulant and nonstimulant medications are efficacious in improving QoL in people with ADHD, albeit with lower effect sizes.

Living with ADHD

Common Comorbidities

ADHD frequently occurs alongside other conditions:- ADHD, or Attention-Deficit/Hyperactivity Disorder, is a neurodevelopmental disorder that is known for its high degree of heterogeneity. It often coexists with other psychiatric diseases, especially anxiety and depression.- The most common psychiatric comorbidities that co-occur with ADHD in adults are depression, anxiety disorders, bipolar disorder, SUDs and personality disorders.- Approximately half (51.0%) of children with current ADHD had two or more co-occurring disorders. The most common co-occurring MEBs were behavioral or conduct problems (44.1%) and anxiety problems (39.1%).

Long-Term Outcomes

Without proper treatment, ADHD can have significant long-term impacts:- Children with ADHD are at increased risk for injuries, social problems, family stress, and poor grades. Teens and adults with ADHD are more likely to engage in risky behaviors, such as substance use and unsafe sexual activity.- ADHD pharmacotherapy is associated with reduced social and emotional impairment, unintentional injuries, substance use disorders, and risk.

Support Strategies

Successful management of ADHD often includes:

  • Developing organizational systems and routines
  • Using external reminders and tools
  • Breaking large tasks into manageable steps
  • Creating structured environments
  • Building support networks
  • Regular exercise and healthy lifestyle habits

Frequently Asked Questions

Q: Can ADHD develop in adulthood, or must symptoms always start in childhood?

A: According to current diagnostic criteria, several inattentive or hyperactive-impulsive symptoms were present before age 12 years. However, many adults receive their diagnosis later in life when symptoms become more apparent or problematic. Some adults may not have been diagnosed with ADHD when younger because their teachers or family did not recognize the disorder, they had a mild form of the disorder, or they managed well until experiencing the demands of adulthood.

Q: Is ADHD overdiagnosed?

A: This remains a topic of debate. Many experts think ADHD is overdiagnosed, largely because criteria are applied inaccurately. However, research also shows that many individuals, particularly women and girls, may be underdiagnosed due to different symptom presentations.

Q: Can ADHD be treated without medication?

A: Yes, non-medication treatments can be effective, especially when used in combination. A total of 37 RCTs involving 2,289 participants and 10 non-pharmacological therapies were included, including cognitive behavioral therapy, mindfulness-based approaches, and neurofeedback. However, medication combined with behavioral interventions often provides the most comprehensive symptom management.

Q: How does ADHD affect relationships?

A: ADHD can impact relationships through difficulties with attention during conversations, forgetfulness about commitments, emotional dysregulation, and impulsive behaviors. Family and marital therapy helps family members learn to handle disruptive behaviors, encourage behavior changes, and improve interactions with children and partners.

Q: Are there differences in how ADHD presents in males versus females?

A: Yes, significant differences exist. Overall, ADHD is approximately twice as common in boys, although the ratios vary by type. The predominantly hyperactive/impulsive type occurs more frequently in boys; the predominantly inattentive type occurs with approximately equal frequency in both sexes. These differences can lead to underdiagnosis in females.

Q: Can lifestyle changes help manage ADHD symptoms?

A: Research suggests certain lifestyle modifications may help: Huang and colleagues (2023) reported small yet statistically significant symptom reductions, especially in inattention, while Dastamooz and colleagues (2023) identified large effects on inattention, but non-significant effects on hyperactivity-impulsivity from physical activity interventions. Regular exercise, adequate sleep, and structured routines can complement other treatments.

How Therapy Can Help / Find a Therapist

Living with ADHD can be challenging, but effective treatment is available. A qualified mental health professional can provide comprehensive assessment, develop an individualized treatment plan, and offer ongoing support for managing symptoms.

Therapy can help individuals with ADHD:

  • Develop coping strategies and organizational skills
  • Address co-occurring conditions like anxiety or depression
  • Improve relationships and communication
  • Build self-esteem and reduce shame
  • Navigate workplace or academic accommodations
  • Create sustainable lifestyle changes

If you or someone you know shows signs of ADHD, consider reaching out to a therapist who specializes in ADHD assessment and treatment. The GoodTherapy directory can help you find qualified professionals in your area who understand the unique challenges of ADHD and can provide evidence-based interventions tailored to your specific needs.

Early intervention and consistent treatment can make a significant difference in managing ADHD symptoms and improving quality of life across all areas of functioning.

References:

  1. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
  2. Ayano, G., Demelash, S., Gizachew, Y., Tsegay, L., & Alati, R. (2023). The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. Journal of Affective Disorders, 339, 860–866. https://doi.org/10.1016/j.jad.2023.07.071
  3. Bellato, A., Perrott, N. J., Marzulli, L., Parlatini, V., Coghill, D., & Cortese, S. (2024). Systematic review and meta-analysis: Effects of pharmacological treatment for attention-deficit/hyperactivity disorder on quality of life. Journal of the American Academy of Child & Adolescent Psychiatry, 64(3), 346–361. https://doi.org/10.1016/j.jaac.2024.05.023
  4. Centers for Disease Control and Prevention. (2024, October 7). Diagnosing ADHD. https://www.cdc.gov/adhd/diagnosis/index.html
  5. Centers for Disease Control and Prevention. (2024, October 10). Attention-deficit/hyperactivity disorder diagnosis, treatment, and telehealth use in adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. MMWR Morbidity and Mortality Weekly Report, 73(40), 890–895. https://www.cdc.gov/mmwr/volumes/73/wr/mm7340a1.htm
  6. Centers for Disease Control and Prevention. (2024, November 19). Data and statistics on ADHD. https://www.cdc.gov/adhd/data/index.html
  7. Chen, M. H., Pan, T. L., Hsu, J. W., Huang, K. L., Su, T. P., Li, C. T., Lin, W. C., Tsai, S. J., Chang, W. H., Chen, T. J., & Bai, Y. M. (2017). Attention-deficit hyperactivity disorder comorbidity and antidepressant resistance among patients with major depression: A nationwide longitudinal study. European Neuropsychopharmacology, 27(3), 239–247. https://doi.org/10.1016/j.euroneuro.2016.12.003
  8. Cortese, S., & Bellgrove, M. A. (2024). Attention‐deficit/hyperactivity disorder (ADHD) in adults: Evidence base, uncertainties and controversies. World Psychiatry, 24(3), 347–371. https://doi.org/10.1002/wps.21374
  9. D'Agati, E., Curatolo, P., & Mazzone, L. (2019). Comorbidity between ADHD and anxiety disorders across the lifespan. International Journal of Psychiatry in Clinical Practice, 23(4), 238–244. https://doi.org/10.1080/13651501.2019.1628277
  10. Danielson, M. L., Claussen, A. H., Bitsko, R. H., Kogan, M. D., Ghandour, R. M., Blumberg, S. J., Cree, R. A., & Cuffe, S. P. (2024). ADHD prevalence among U.S. children and adolescents in 2022: Diagnosis, severity, co-occurring disorders, and treatment. Journal of Clinical Child & Adolescent Psychology, 53(3), 343–360. https://doi.org/10.1080/15374416.2024.2335625
  11. Dastamooz, S., Sadeghi-Bahmani, D., Farahani, M. H. D., Wong, S. H. S., Yam, J. C. S., Sit, C. H. P., Khazaie, H., & Brand, S. (2025). The effects of physical activity interventions on the core symptoms of ADHD in adults: A systematic review and meta-analysis. Mental Health and Physical Activity. https://doi.org/10.1016/j.mhpa.2025.100560
  12. Dimitrov, L. V., Kaminski, J. W., Holbrook, J. R., Bitsko, R. H., Yeh, M., Courtney, J. G., O'Masta, B., Maher, B., Cerles, A., McGowan, K., & Rush, M. (2024). A systematic review and meta-analysis of chemical exposures and attention-deficit/hyperactivity disorder in children. Prevention Science, 25(Suppl 2), 225–248. https://doi.org/10.1007/s11121-023-01601-6
  13. Faix, X., Wang, W., Wang, Y., Liu, X., Wang, R., Li, W., & Liu, Y. (2025). Adult ADHD and comorbid anxiety and depressive disorders: A review of etiology and treatment. Frontiers in Psychiatry, 16, 1597559. https://doi.org/10.3389/fpsyt.2025.1597559
  14. Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017). Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry, 17(1), 302. https://doi.org/10.1186/s12888-017-1463-3
  15. Koutsoklenis, A., & Honkasilta, J. (2023). ADHD in the DSM-5-TR: What has changed and what has not. Frontiers in Psychiatry, 13, 1064141. https://doi.org/10.3389/fpsyt.2022.1064141
  16. Koyuncu, A., Çelebi, F., Ertekin, E., Kök, B. E., & Tükel, R. (2025). Comorbidity of attention deficit hyperactivity disorder in young adults who had major depressive disorder. Annals of Saudi Medicine, 45(2), 87–95. https://doi.org/10.5144/0256-4947.2025.87
  17. Li, Y., Yan, Q., Li, Q., Yang, W., & Lu, J. (2023). Prevalence and trends in diagnosed ADHD among US children and adolescents, 2017-2022. JAMA Network Open, 6(10), e2336872. https://doi.org/10.1001/jamanetworkopen.2023.36872
  18. Merck Manual Professional Edition. (2024, September). Attention-deficit/hyperactivity disorder (ADHD). https://www.merckmanuals.com/professional/pediatrics/learning-and-developmental-disorders/attention-deficit-hyperactivity-disorder-adhd
  19. National Institute of Mental Health. (2024). Attention-deficit/hyperactivity disorder. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
  20. National Institute of Mental Health. (2024). Attention-deficit/hyperactivity disorder: What you need to know. https://www.nimh.nih.gov/sites/default/files/documents/health/publications/adhd-2024.pdf
  21. National Institute of Mental Health. (2024, March). NIH researchers identify brain connections associated with ADHD in youth. https://www.nimh.nih.gov/news/science-updates/2024/nih-researchers-identify-brain-connections-associated-with-adhd-in-youth
  22. National Institute of Mental Health. (2024). Optimizing treatment strategies for adult attention-deficit hyperactivity disorder (ADHD). https://www.nimh.nih.gov/funding/grant-writing-and-application-process/concept-clearances/2024/optimizing-treatment-strategies-for-adult-attention-deficit-hyperactivity-disorder-adhd
  23. Norman, L. J., Sudre, G., Price, J., & Shaw, P. (2024). Subcortico-cortical dysconnectivity in ADHD: A voxel-wise mega-analysis across multiple cohorts. American Journal of Psychiatry. https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.20230026
  24. Ostinelli, E. G., Brooke-Powney, M. J., Li, X., Bi, C., Chen, S., Mohammad, Z., Kennedy, B., Chua, K. C., Yang, C., Sharma, R., Agrawal, P., Baldwin, D. S., Chamberlain, S. R., Cleare, A. J., Correll, C. U., Hughes, T., Huneke, N. T. M., Kirkham, E., Nutt, D. J., Palpacuer, C., Pratt, R., Singh, S. P., Solmi, M., & Cortese, S. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis. The Lancet Psychiatry, 12(1), 41-59. https://doi.org/10.1016/S2215-0366(24)00360-2
  25. Paul, M. L., Howard, A. L., Best, L. M., Cunill, R., Castells, X., Lichtenstein, P., D'Onofrio, B. M., Faraone, S. V., & Chang, Z. (2024). Incidence of attention‐deficit/hyperactivity disorder between 2016 and 2023: A retrospective cohort. Psychiatric Research and Clinical Practice. In Advance. https://doi.org/10.1176/appi.prcp.20240121
  26. Popit, S., Banko, L., Kurent, I. B., Jerala, T., Sustar, U., Psenicnik, A., Anzeljc, L. G., Kokalj, M., & Anzic, S. A. (2024). Prevalence of attention-deficit hyperactivity disorder (ADHD): Systematic review and meta-analysis. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1786
  27. Ranjan, J. K., Kumari, R., & Choudhary, A. (2024). Prevalence of attention deficit and hyperactive disorders in South Asian countries: A systematic review and meta-analysis of cross-sectional surveys from 1980 to 2023. Asian Journal of Psychiatry, 94, 103970. https://doi.org/10.1016/j.ajp.2024.103970
  28. West Virginia ADHD Guidelines. (2023). DSM-5 to DSM-5-TR modifications to attention-deficit/hyperactivity disorder (ADHD) chapter. https://wvadhd.org/wp-content/uploads/2023/08/Appendix-1.1-DSM-5-to-DSM-5-TR-Modifications-to-ADHD-Chapter.pdf
  29. Wolraich, M. L., Hagan, J. F. Jr., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W.; Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528
  30. Yin, Y., Tong, F., & Peng, C. (2025). Short-term and long-term effect of non-pharmacotherapy for adults with ADHD: A systematic review and network meta-analysis. Frontiers in Psychiatry, 16, 1516878. https://doi.org/10.3389/fpsyt.2025.1516878